

Special Issue

Drug Candidates from Venoms

Message from the Guest Editor

Venoms derived from a large variety of organisms have captivated human civilizations for centuries. This Special Issue on Drug Candidates from Venoms aims to report on current state-of-the-art venom-based drug discovery efforts that are largely centered on one of the following areas. First, the comprehensive chemical characterization of novel venom components using 'omics' technology. Second, the discovery of new molecular targets and the mechanism of action of novel venom components. Lastly, the discovery of re-engineered venom compounds using both computational modelling and medicinal chemistry approaches. Such studies are expected to be foundational in yielding the next generation of novel drug candidates for possible therapeutic use in human diseases, as well as expanding applications in agriculture and veterinary care.

Guest Editor

Dr. Craig Doupnik

Department of Molecular Pharmacology & Physiology, University of South Florida College of Medicine, Tampa, FL 33612, USA

Deadline for manuscript submissions

closed (31 August 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/114952

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)